
- /
- Supported exchanges
- / US
- / MNKD.NASDAQ
MannKind Corp (MNKD NASDAQ) stock market data APIs
MannKind Corp Financial Data Overview
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get MannKind Corp data using free add-ons & libraries
Get MannKind Corp Fundamental Data
MannKind Corp Fundamental data includes:
- Net Revenue: 298 M
- EBITDA: 86 360 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: 0.06
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MannKind Corp News

High Growth Tech Stocks To Watch In The US July 2025
As the United States market navigates a complex landscape marked by trade policy uncertainties and fluctuating economic indicators, major indices like the Dow Jones Industrial Average and S&P 500 rema...


Wells Fargo Maintains a Buy Rating on MannKind Corporation (MNKD), Sets a $9 PT
MannKind Corporation (NASDAQ:MNKD) is one of the 13 Best Healthcare Stocks to Buy Under $10. On May 8, Wells Fargo analyst Tiago Fauth maintained a Buy rating on MannKind Corporation (NASDAQ:MNKD) and...

MannKind Corp stock hits 52-week low at $3.63
MannKind Corp (NASDAQ:MNKD)’s stock recently reached a 52-week low, trading at $3.63. Despite the current price weakness, InvestingPro data shows the company maintains strong fundamentals with a he...

Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock?
Amarin (AMRN) shares rallied 27.3% in the last trading session to close at $16.04. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.